Company
Headquarters: Baudette, MN, United States
Employees: 601
CEO: Mr. Nikhil Lalwani
$1.23 Billion
USD as of Jan. 1, 2025
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | $555.5 M |
| EBITDA | $109.2 M |
| Gross Profit TTM | $332.1 M |
| Profit Margin | -1.28% |
| Operating Margin | -7.34% |
| Quarterly Revenue Growth | 12.50% |
ANI Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: ANIP wb_incandescent
Stock: FSX: BSFA wb_incandescent
Stock: XSTU: BSFA wb_incandescent